

Resource Summary Report

Generated by [NIF](#) on Aug 31, 2026

B16-F10

RRID:CVCL_0159

Type: Cell Line

Proper Citation

RCB Cat# RCB2630, RRID:CVCL_0159

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0159

Proper Citation: RCB Cat# RCB2630, RRID:CVCL_0159

Description: Cell line B16-F10 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Male

Disease: Mouse melanoma

Defining Citation: [PMID:210294](#), [PMID:1109790](#), [PMID:6539703](#), [PMID:11833741](#), [PMID:23890195](#), [PMID:25277546](#), [PMID:30084848](#)

Comments: Characteristics: Has a high metastatic potential., Characteristics: Obtained from the pulmonary melanoma module of the 10th serial passage of the B16-F0 parent cell line in C57BL/6 mice.

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: B16-F10

Synonyms: B16/F10, B16 F10, B16F10, B16 melanoma F10

Cross References: BTO:BTO_0002014, CLO:CLO_0001794, CLO:CLO_0050763, EFO:EFO_0022759, MCCL:MCC:0000051, CLDB:cl339, CLDB:cl4967, AddexBio:C0012005/5003, ATCC:CRL-6475, BCRC:60031, BCRJ:0046, BioGRID_ORCS_Cell_line:737, CCRID:1101MOU-PUMC000473, CCRID:3101MOUTCM36, CCRID:6101MOU-CERC000106, ChEMBL-Cells:ChEMBL3307762, ChEMBL-Targets:ChEMBL612656, CLS:305157, ICLC:ATL99010, KCB:KCB 2014047YJ, KCLB:80008, Lonza:998, NCBI_Iran:C540, NCI-DTP:B16F10, PRIDE:PX008733, PubChem_Cell_line:CVCL_0159, RCB:RCB2630,

TKG:TKG 0348, Ubigen:YC-A011, Wikidata:Q54752438

ID: CVCL_0159

Vendor: RCB

Catalog Number: RCB2630

Hierarchy: cvcl_uj41

Record Creation Time: 20220427T215231+0000

Record Last Update: 20260830T002309+0000

Ratings and Alerts

No rating or validation information has been found for B16-F10.

No alerts have been found for B16-F10.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 3937 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pan D, et al. (2026) DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy. Cancer research, 86(12), 3026.

Yang Q, et al. (2026) MSH6 regulates cGAS activity in antiviral and antitumor signaling pathways by governing its cytosolic/nuclear distribution. Cell reports, 45(3), 117059.

Smits D, et al. (2026) Glycocalyx micro- and nanodomains in cell-cell and cell-matrix interactions revealed by enhanced click chemistry. Nature communications, 17(1).

Chen S, et al. (2026) 16-h fasting optimizes cancer immunotherapy in mice and humans. Cell metabolism, 38(5), 944.

Maltez VI, et al. (2026) Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment. Immunity, 59(4), 1058.

Yang Y, et al. (2026) Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8+ T cells. Journal for immunotherapy of cancer, 14(3).

Qiao L, et al. (2026) A Natural Sweetener-inducible Genetic Switch Controls Therapeutic Protein Expression in Mammals. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e14226.

Li Y, et al. (2026) Tumor-Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T-Cell Infiltration and Limiting Myeloid Cell-Mediated Immunosuppression. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(38), e23895.

Sun Y, et al. (2026) Discovery of TYR inhibitors from de novo molecular generation to dual-track lead optimization: "Competition" between AI and chemists. *Science advances*, 12(25), eaeg0376.

Xiong T, et al. (2026) Small-Molecule Boron-10-Enriched Carriers with Exceptional Aqueous Solubility for Enhanced Boron Neutron Capture Therapy of Malignant Tumors. *Research* (Washington, D.C.), 9, 1315.

Jiang H, et al. (2026) IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy. *Immunity*, 59(1), 177.

Zitti B, et al. (2026) Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity. *Immunity*, 59(1), 161.

Liu A, et al. (2026) Soluble Uric Acid Drives CD8+ T-cell Exhaustion by Inducing KSR1-Mediated MAPK Hyperactivation. *Cancer research*, 86(14), 3459.

Lee H, et al. (2026) PLD1 and PLD2 promote an immunosuppressive tumor microenvironment via CCL19-dependent macrophage polarization and PD-L1 induction. *Experimental & molecular medicine*, 58(6), 1870.

Li S, et al. (2026) Rationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies. *Trends in biotechnology*.

Sahm BDB, et al. (2026) Anticancer Potential of Piericidin A1 and Derivatives Isolated From *Streptomyces* sp. Associated With *Palythoa variabilis* From Brazilian Reefs. *Chemistry & biodiversity*, 23(4), e03815.

Hu Y, et al. (2026) Irradiated Tumor Cell-Derived Microparticles Activate Systemic Anti-Tumor Immunity via the STING/NLRP3/GSDMD Axis in Neutrophils. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e14390.

Angeli S, et al. (2026) Modulating tumor mechanics and vascular barriers to enhance chemotherapy efficacy in pancreatic tumors and melanoma. *Journal of controlled release : official journal of the Controlled Release Society*, 390, 114546.

Agesta A, et al. (2026) The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapy. *Immunity*, 59(7), 1876.

Bashir H, et al. (2026) Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth. *Cancer cell*, 44(7), 1458.